Transcriptomics

Dataset Information

0

A Novel Combination Therapy with Uridine and Praziquantel effectively Alleviates Schistosomiasis-induced Hepatic Fibrosis through Promoting Adipogenic Differentiation


ABSTRACT: Schistosomiasis-induced hepatic fibrosis, a consequence of egg-induced granulomatous lesions, remains untreated by current drugs. Therefore, the development of novel antifibrosis drugs is of paramount importance. Our previous study indicated that aberrant uridine concentrations play a pivotal role in schistosomiasis-induced hepatic fibrosis. This study aimed to explore the inhibitory role of uridine in schistosomiasis-induced liver fibrosis and the regulatory mechanism of uridine on hepatic stellate cell (HSC) activation. The results indicated that uridine could inhibit schistosomiasis-induced liver fibrosis in vivo and TGF-β-induced HSC activation in vitro. Molecular docking revealed a strong interaction between uridine and the adenosine receptor A1 (ADORA1) receptor. Subsequent in vitro investigations demonstrated that uridine modulated the cAMP/PKA/CREB pathway, influencing HSC adipogenic differentiation and exerting an antifibrotic effect. In addition, compared with praziquantel (PZQ) alone, combined uridine and PZQ therapy resulted in a reduced fibrotic area and improved hepatic parameters in vivo. Our study reveals the antifibrosis mechanism of the uridine molecule, which may be a promising drug for the treatment of schistosomiasis-induced liver fibrosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE289753 | GEO | 2025/04/22

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2014-08-31 | E-GEOD-59276 | biostudies-arrayexpress
2014-08-31 | GSE59276 | GEO
| PRJNA1224445 | ENA
2023-04-22 | GSE114506 | GEO
2019-02-26 | GSE120682 | GEO
2011-05-27 | GSE29535 | GEO
2008-11-10 | GSE12850 | GEO
2011-05-27 | E-GEOD-29535 | biostudies-arrayexpress
2022-12-16 | GSE220286 | GEO
2008-11-10 | E-GEOD-12850 | biostudies-arrayexpress